Medicines Company's Inclisiran Succeeds In Pivotal Studies
Zacks Investment Research | Sep 26, 2019 12:05AM ET
The Medicines Company (NASDAQ:MDCO) announced that its PCSK9 inhibitor candidate, inclisiran, met primary as well as secondary endpoints in two pivotal phase III studies — ORION-9 and ORION-10 — evaluating it in heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD), respectively.
In the studies, inclisiran demonstrated durable and potent efficacy. Safety data from these studies showed that no treatment-related liver or renal laboratory abnormalities were observed.
Detailed data from these studies will be presented at the American Heart Association Scientific Sessions in Philadelphia scheduled to be held in November.
The completion of ORION-9 and ORION-10 studies along with recently completed industry ’s decline of 3.2%.
The Medicines Company is currently enrolling patients who have completed any of three phase III studies in the ORION program in open-label, long-term extension study — ORION-8.
Please note that The Medicines Company is developing inclisiran in partnership with Alnylam Pharmaceuticals (NASDAQ:ALNY) .
Meanwhile, the company presented detailed data from the ORION-11 study at the European Society of Cardiology’s ESC Congress 2019 earlier this month. Data showed that twice a year administration of inclisiran achieved a placebo-adjusted 54% reduction in LDL-C levels at day 510 in patients with ASCVD or ASCVD-risk equivalents and elevated LDL-C, following treatment with maximum tolerated dose of statin therapy alone or in combination with Merck’s (NYSE:MRK) Zetia. Moreover, time-adjusted reduction in LDL-C levels following treatment with inclisiran was 50%, which was sustained over 18 months of treatment.
We note that there are already two approved PCSK9 inhibitors — Sanofi/Regeneron’s Praluent and Amgen’s (NASDAQ:AMGN) Repatha — for treating hypercholesterolemia. However, accessibility of these drugs is hampered by high co-pay expenses and payer restrictions. This led to 60% reduction in list prices of Repatha and Praluent in the United States last year.
Although less frequent dosing of inclisiran compared to Repatha and Praluent may prove advantageous for the candidate following its potential approval, it is also likely to face challenges like high co-pay expenses and payer restrictions during commercialization.
Get The News You Want
The Medicines Company Price
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.